Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Proliferative Diabetic Retinopathy (PDR)~* Indicated for vitrectomy~Exclusion Criteria:~* History of intraocular surgery, intravitreal injection of drugs or sub-Tenon injection of steroids or retinal photocoagulation within 6 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab injection and vitrectomy (Type: ACTIVE_COMPARATOR): 0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
- Sham injection and vitrectomy (Type: SHAM_COMPARATOR): Sham injection one day before vitrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).